Summit Healthcare (NASDAQ:SMIH) announced that its shareholders have approved its combination with drug-maker YS Biopharma at a special meeting held earlier today.
The SPAC did not disclose redemption figures, but noted that the transaction is expected to deliver approximately $36 million in gross proceeds, which are expected to be used for the clinical development and future commercialization of the company’s vaccines.
The parties expect to officially close the deal on Thursday, March 16, 2023. YS Biopharma will remain as the combined company and its shares and warrants are expected to begin trading on the Nasdaq Capital Market under the symbols “YS” and “YSBPW,” respectively, on Friday, March 17, 2023.
Summit announced the $1 billion deal with YS Biopharma in September 2022. The Beijing-based company currently makes a rabies vaccine for the Chinese market and is working to commercialize a range of new vaccines and other treatments.
Upon closing of the transaction, Mr. Bo Tan, the CEO, Co-Chief Investment Officer, and director of Summit, will join YS Biopharma’s board of directors. The board of directors of YS Biopharma will consist of seven directors, including two current directors of YS Biopharma, Mr. Bo Tan, and four independent directors.
ADVISORS
- Wilson Sonsini Goodrich & Rosati is serving as legal advisors to YS Biopharma
- Jingtian & Gongcheng is serving as legal advisors to YS Biopharma
- Maples Group is serving as legal advisors to YS Biopharma
- Cooley LLP and Ogier are serving as legal advisors to Summit
Ares Acquisition Corporation II (NYSE:AACT) filed its S-1 yesterday afternoon for a $400 million IPO, marking the second SPAC to file for an IPO in March and the largest since December 20, 2021, when Gores Holdings X Inc. filed for a $725 million SPAC. Ares II intends to focus its search on an established target...
Latest SPAC Liquidations: TCV Acquisition Corp. TCV Acquisition Corp. (TCVA) to Liquidate on April 13 TCV Acquisition Corp. (Nasdaq: TCVA) announced that it intends to dissolve and liquidate. It will redeem all of the outstanding Class A ordinary shares that were included in its initial public offering at a per-share redemption price of approximately $10.24. As...
DiamondHead Holding Corps. (NASDAQ:DHHC) announced that it has closed its combination with Great Southern Homes and the combined company will be renamed United Homes Group. The deal was approved by shareholders during a meeting last Thursday, and only 109,426 shares were redeemed in connection with the vote, but DiamondHead saw about 87% redemptions in total...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Volta sued over SPAC deal, Liberty Resources establishes M&A Transition Taskforce, and chancery validates SPACs’ charter amendments and share issuances Volta Sued Over SPAC Deal as $169M Shell Sale Is Approved An investor sued...
Maxpro Capital (NASDAQ:JMAC) announced that it has closed its combination with clinical-stage biotech firm Apollomics and the combined company’s shares and warrants are to begin trading today on the Nasdaq under the symbols “APLM” and “APLMW”, respectively. Apollomics is set to receive $21.35 million in proceeds from a PIPE that Maxpro announced in February and...